© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Neeraj Agarwal, MD, and Simon Chowdhury, MD, review final results from the TITAN study of apalutamide in patients with mCSPC and discuss the clinical implications of the findings.
December 23rd 2021
Neeraj Agarwal, MD, and Simon Chowdhury, MD, examine the efficacy and safety data presented in the recent publication, “Apalutamide in Patients with Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.”
January 12th 2022
Drs Agarwal and Chowdhury analyze the survival data from the phase 3 TITAN study of apalutamide in men with mCSPC.
January 17th 2022
Neeraj Agarwal, MD, and Simon Chowdhury, MD, comment on the secondary end points from the final analysis of the TITAN trial.
January 24th 2022
GU oncologists discuss toxicities from androgen deprivation therapy and apalutamide as reported in the phase 3 TITAN study.